Physician profile
Andrew J Maxwell
NPI 1922116789
$1,172.42
in general payments reported to CMS, 2019-2025
15 companies · $74.78 in 2025
The $74.78 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $88.07 · 2021: $118 · 2022: $109 · 2023: $215 · 2024: $351 · 2025: $74.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $302.67 | 2021-2024 | Qelbree |
| Tris Pharma INC | $126.69 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $119.06 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $115.01 | 2019-2023 | Jornay Pm |
| Corium, LLC | $112.60 | 2022-2024 | Azstarys |
| Biogen, INC. | $98.12 | 2023-2024 | Spinraza |
| Merck Sharp & Dohme LLC | $70.83 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $64.81 | 2019-2022 | |
| Adlon Therapeutics L.P. | $36.06 | 2020-2021 | |
| Sanofi Pasteur INC. | $34.48 | 2019-2025 | |
| Harmony Biosciences LLC | $21.58 | 2024 | |
| Mirum Pharmaceuticals, INC. | $20.79 | 2025 | Cholbam |
| Ars Pharmaceuticals Operations, INC. | $19.01 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $15.69 | 2022 | |
| Biomarin Pharmaceutical INC. | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.